Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(50.0%)
USD 0.15
(50.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.32 Million USD | 0.0% |
| 2022 | 2.32 Million USD | 21.31% |
| 2021 | 1.91 Million USD | -9.24% |
| 2020 | 2.11 Million USD | 18.0% |
| 2019 | 1.79 Million USD | 38.74% |
| 2018 | 1.29 Million USD | -14.52% |
| 2017 | 1.5 Million USD | -2.89% |
| 2016 | 1.55 Million USD | 7.89% |
| 2015 | 1.44 Million USD | -32.94% |
| 2014 | 2.14 Million USD | 2097.77% |
| 2013 | 97.76 Thousand USD | -29.46% |
| 2012 | 138.58 Thousand USD | 947.54% |
| 2011 | 13.23 Thousand USD | -72.7% |
| 2010 | 48.45 Thousand USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 7.66 Million USD | -74.74% |
| 2006 | 30.35 Million USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.24 Million USD | -2.38% |
| 2024 Q3 | 2.21 Million USD | -1.14% |
| 2024 Q1 | 2.29 Million USD | -1.17% |
| 2023 Q3 | 2 Million USD | -2.22% |
| 2023 FY | 2.32 Million USD | 0.0% |
| 2023 Q2 | 2.05 Million USD | -0.9% |
| 2023 Q4 | 2.32 Million USD | 15.98% |
| 2023 Q1 | 2.06 Million USD | 7.94% |
| 2022 FY | 2.32 Million USD | 21.31% |
| 2022 Q1 | 2.05 Million USD | -2.51% |
| 2022 Q2 | 1.93 Million USD | -6.03% |
| 2022 Q3 | 1.92 Million USD | -0.8% |
| 2022 Q4 | 1.91 Million USD | -0.14% |
| 2021 Q1 | 1.86 Million USD | -1.98% |
| 2021 Q4 | 2.11 Million USD | 9.35% |
| 2021 Q2 | 1.92 Million USD | 3.18% |
| 2021 Q3 | 1.93 Million USD | 0.29% |
| 2021 FY | 1.91 Million USD | -9.24% |
| 2020 Q1 | 1.49 Million USD | -16.31% |
| 2020 FY | 2.11 Million USD | 18.0% |
| 2020 Q2 | 1.5 Million USD | 0.55% |
| 2020 Q3 | 1.65 Million USD | 9.85% |
| 2020 Q4 | 1.9 Million USD | 15.09% |
| 2019 FY | 1.79 Million USD | 38.74% |
| 2019 Q4 | 1.79 Million USD | 33.71% |
| 2019 Q2 | 1.32 Million USD | 1.24% |
| 2019 Q3 | 1.33 Million USD | 1.24% |
| 2019 Q1 | 1.3 Million USD | 1.24% |
| 2018 Q1 | 1.33 Million USD | -11.86% |
| 2018 FY | 1.29 Million USD | -14.52% |
| 2018 Q4 | 1.29 Million USD | -1.98% |
| 2018 Q3 | 1.31 Million USD | 3.53% |
| 2018 Q2 | 1.27 Million USD | -4.43% |
| 2017 Q3 | 1.51 Million USD | -0.07% |
| 2017 FY | 1.5 Million USD | -2.89% |
| 2017 Q1 | 1.51 Million USD | -2.48% |
| 2017 Q2 | 1.51 Million USD | -0.03% |
| 2017 Q4 | 1.5 Million USD | -0.31% |
| 2016 FY | 1.55 Million USD | 7.89% |
| 2016 Q2 | 1.53 Million USD | 3.28% |
| 2016 Q1 | 1.48 Million USD | 2.86% |
| 2016 Q3 | 1.61 Million USD | 5.61% |
| 2016 Q4 | 1.55 Million USD | -3.84% |
| 2015 Q4 | 1.44 Million USD | -6.14% |
| 2015 Q1 | 1.43 Million USD | -33.31% |
| 2015 Q2 | 1.44 Million USD | 1.05% |
| 2015 Q3 | 1.53 Million USD | 6.03% |
| 2015 FY | 1.44 Million USD | -32.94% |
| 2014 Q2 | 1.43 Million USD | -1.5% |
| 2014 Q1 | 1.45 Million USD | 1385.57% |
| 2014 Q3 | 1.45 Million USD | 1.35% |
| 2014 FY | 2.14 Million USD | 2097.77% |
| 2014 Q4 | 2.14 Million USD | 48.18% |
| 2013 Q1 | 132.32 Thousand USD | -4.52% |
| 2013 Q2 | 116.25 Thousand USD | -12.14% |
| 2013 FY | 97.76 Thousand USD | -29.46% |
| 2013 Q3 | 110.39 Thousand USD | -5.04% |
| 2013 Q4 | 97.76 Thousand USD | -11.44% |
| 2012 Q2 | 4062.00 USD | -50.35% |
| 2012 Q3 | 1024.00 USD | -74.79% |
| 2012 Q4 | 138.58 Thousand USD | 13434.08% |
| 2012 FY | 138.58 Thousand USD | 947.54% |
| 2012 Q1 | 8181.00 USD | -38.16% |
| 2011 FY | 13.23 Thousand USD | -72.7% |
| 2011 Q2 | 31.23 Thousand USD | -22.52% |
| 2011 Q4 | 13.23 Thousand USD | -37.68% |
| 2011 Q3 | 21.22 Thousand USD | -32.03% |
| 2011 Q1 | 40.31 Thousand USD | -16.81% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | 48.45 Thousand USD | 0.0% |
| 2010 FY | 48.45 Thousand USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | -100.0% |
| 2008 Q1 | 2.56 Million USD | -66.55% |
| 2007 Q1 | 26.62 Million USD | -12.3% |
| 2007 Q2 | 18.9 Million USD | -28.99% |
| 2007 Q3 | 13.03 Million USD | -31.03% |
| 2007 Q4 | 7.66 Million USD | -41.18% |
| 2007 FY | 7.66 Million USD | -74.74% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | 30.35 Million USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | 30.35 Million USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 94.355% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 43.572% |
| SQZ Biotechnologies Company | 27.47 Million USD | 91.533% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 94.637% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 92.186% |
| Mesoblast Limited | 118.7 Million USD | 98.04% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -145.284% |
| Genus plc | 233.1 Million USD | 99.002% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 20.626% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -73.116% |
| Marizyme, Inc. | 18.71 Million USD | 87.573% |
| ContraFect Corporation | 2.88 Million USD | 19.266% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -210.127% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -1616.737% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -60.819% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 58.893% |
| MultiCell Technologies, Inc. | 202.58 USD | -1148066.157% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 95.954% |
| EV Biologics, Inc. | 1.49 Million USD | -55.608% |
| Q BioMed Inc. | 4.1 Million USD | 43.407% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 92.973% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -269.154% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -89.354% |
| Biomind Labs Inc. | 735.54 Thousand USD | -216.223% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 98.644% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 82.104% |
| Skye Bioscience, Inc. | 4.61 Million USD | 49.603% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -161.913% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -1543.575% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 60.383% |
| IMV Inc. | 28.88 Million USD | 91.947% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -8943.723% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -2.992% |
| GB Sciences, Inc. | 1.75 Million USD | -32.209% |
| Alpha Cognition Inc. | 1.22 Million USD | -90.594% |
| HST Global, Inc. | 98.31 Thousand USD | -2265.723% |
| CSL Limited | 12.18 Billion USD | 99.981% |
| Halberd Corporation | 150 Thousand USD | -1450.637% |
| Enzolytics Inc. | 996.33 Thousand USD | -133.45% |
| Resverlogix Corp. | 6.49 Million USD | 64.166% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -387.111% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -810.027% |
| argenx SE | 20 Million USD | 88.37% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 94.895% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 14.13% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -22647.726% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.443% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1059.407% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 2.993% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -914.412% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 96.561% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 23.139% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -546.619% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 88.558% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -1464.677% |
| BioStem Technologies, Inc. | 4.71 Million USD | 50.632% |
| ONE Bio Corp. | 19.71 Million USD | 88.202% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -829.705% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -835.17% |
| Agentix Corp. | 50 Thousand USD | -4551.91% |
| LadRx Corporation | 33.6 Thousand USD | -6821.249% |
| Cell Source, Inc. | 9.25 Million USD | 74.866% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -207.583% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -207.583% |
| NovAccess Global Inc. | 2.19 Million USD | -5.731% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 67.114% |
| Itoco Inc. | 228.37 Thousand USD | -918.472% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1002.479% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 53.322% |
| Kadimastem Ltd | 891.22 Thousand USD | -160.984% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -478.813% |
| CytoDyn Inc. | 30.07 Million USD | 92.266% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -380.287% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -561.07% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 70.256% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -1798.739% |
| Rebus Holdings, Inc. | 310 Thousand USD | -650.308% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 50.88% |
| International Stem Cell Corporation | 4.17 Million USD | 44.329% |
| Bioxytran, Inc. | 1.92 Million USD | -20.829% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3626.716% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -6.651% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 72.03% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 72.907% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -49.533% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -767.894% |
| Neutra Corp. | 54.15 Thousand USD | -4194.917% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -27.101% |
| PureTech Health plc | 25.51 Million USD | 90.883% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -89.994% |
| IXICO plc | 472.02 Thousand USD | -392.763% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 84.995% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 96.264% |
| CSL Limited | 12.18 Billion USD | 99.981% |
| Cellectis S.A. | 92.77 Million USD | 97.493% |